Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity.

Zeuner, Kirsten E; Deuschl, Günther

Zeuner, Kirsten E; Deuschl, Günther.

Affiliation

Zeuner KE; a Department of Neurology , Christian Albrechts University Kiel , Kiel , Germany.
Deuschl G; a Department of Neurology , Christian Albrechts University Kiel , Kiel , Germany.

Expert Opin Drug Metab Toxicol ; 12(4): 457-66, 2016.

Article in En | MEDLINE | ID: mdl-26882333

Subject(s)

Botulinum Toxins, Type A/administration & dosage; Botulinum Toxins, Type A/pharmacokinetics; Muscle Spasticity/drug therapy; Stroke/drug therapy; Activities of Daily Living; Clinical Trials, Phase III as Topic; Humans; Neuromuscular Agents/administration & dosage; Neuromuscular Agents/pharmacokinetics; Non-Randomized Controlled Trials as Topic; Quality of Life; Treatment Outcome

Key words

Xeomin; botulinum toxin A; incobotulinumtoxinA; pharmacodynamics; pharmacology; post-stroke spasticity; spasticity; treatment efficacy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Botulinum Toxins, Type A / Stroke / Muscle Spasticity Type of study: Observational_studies / Risk_factors_studies / Systematic_reviews Aspects: Patient_preference Limits: Humans Language: En Journal: Expert Opin Drug Metab Toxicol Journal subject: METABOLISMO / TOXICOLOGIA Year: 2016 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google